Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Net revenues:
Total net revenues	$ 1,577	$ 2,309	$ 4,106	$ 4,078
Cost of goods sold	682	942	1,720	1,713
Gross margin	895	1,367	2,386	2,365
Operating expenses:
Research and development	836	793	1,399	1,549
Depreciation and amortization	47	48	93	98
Selling, general and administrative	1,610	1,403	3,560	2,906
Change in fair value of contingent consideration		(9)	(42)	(19)
Total operating expenses	2,493	2,235	5,010	4,534
Loss from operations	(1,598)	(868)	(2,624)	(2,169)
Other (expense) income:
Interest expense	(30)	(46)	(73)	(92)
Interest income	4		5
Other expense, net	(33)	(28)	(63)	(30)
Net loss	(1,657)	(942)	(2,755)	(2,291)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(60)	(61)	(119)	(120)
Net loss attributable to Nephros, Inc. shareholders	$ (1,717)	$ (1,003)	$ (2,874)	$ (2,411)
Net loss per common share, basic and diluted	$ (0.19)	$ (0.14)	$ (0.33)	$ (0.33)
Weighted average common shares outstanding, basic and diluted	8,986,134	7,387,930	8,788,182	7,259,491
Comprehensive loss:
Net loss	$ (1,657)	$ (942)	$ (2,755)	$ (2,291)
Other comprehensive (loss) income, foreign currency translation adjustments, net of tax	1	2		(1)
Comprehensive loss	(1,656)	(940)	(2,755)	(2,292)
Comprehensive loss attributable to noncontrolling interest	(60)	(61)	(119)	(120)
Comprehensive loss attributable to Nephros, Inc. shareholders	(1,716)	(1,001)	(2,874)	(2,412)
Product Revenues [Member]
Net revenues:
Total net revenues	1,564	2,284	4,039	4,013
Royalty and Other Revenues [Member]
Net revenues:
Total net revenues	$ 13	$ 25	$ 67	$ 65